Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Apr;23(2):176-84.
doi: 10.3346/jkms.2008.23.2.176.

Cost-benefit analysis of haemophilus influenzae type B immunization in Korea

Sangjin Shin  1 , Young-jeon Shin, Moran Ki
Affiliations

Cost-benefit analysis of haemophilus influenzae type B immunization in Korea

Sangjin Shin et al. J Korean Med Sci. 2008 Apr.

Abstract

An economic evaluation of Haemophilus influenzae type b (Hib) immunization was conducted to examine whether Hib immunization should be included in Korea's national immunization program. The costs and benefits included direct and indirect values and an estimation of the economic efficiency. We determined that a universal Hib immunization program in Korea would prevent 17 deaths and 280 invasive Hib cases. When we assumed the one Hib immunization cost as 26,000 won, the national Hib immunization would cost 34.6 billion won. Costs for various Hib diseases were estimated at 26.8 billion won (11.8 billion won from direct costs and 14.9 billion won from indirect costs). A benefit-cost ratio of 0.77 showed that the economic efficiency of the integration of Hib immunization in Korea is low because of the low incidence rate of Hib disease and high price of vaccine. However, if the Hib immunization cost decrease to less than 20,000 won, a benefit-cost ratio increase to 1.0 and above, integrating Hib immunization into the national immunization program with economic efficiency can be considered.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Hib immunization decision tree.
See this image and copyright information in PMC

Comment in

  • Is Hib vaccine of economic value in South Korea?
    Griffiths UK, Edmond K, Hajjeh R. Griffiths UK, et al. J Korean Med Sci. 2009 Feb;24(1):187; author reply 188. doi: 10.3346/jkms.2009.24.1.187. Epub 2009 Feb 28. J Korean Med Sci. 2009. PMID: 19270839 Free PMC article. No abstract available.

References

    1. WHO. Global Programme for Vaccines and Immunizations (GPV). The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol Rec. 1998;73:64–68. - PubMed
    1. Schillinger J, Schwartz B, Perkins B, Wenger J. Global burden of bacterial meningitis. In: Murray CJL, Lopez A, editors. The global burden of diseases. Boston: Harvard School of Public Health (on behalf of the World Health Organization and the World Bank); 1996.
    1. WHO. Introduction of Haemophilus influenzae type b vaccine into immunization programmes: Department of Vaccines and Biologicals. WHO; 2000.
    1. Levine OS, Schwartz B, Pierce N, Kane M. Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions. Pediatr Infect Dis J. 1998;17(9 Suppl):S95–S113. - PubMed
    1. Immunization. WHO Regional Office for the Western Pacific; [cited 2007. May 20]. Available from:URL: http://www.wpro.who.int/health_topics/immunization/general_info.htm.

Substances